CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negat

Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clini

   At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembro

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembroliz

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for onco

Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on tr

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transc

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage b

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweigh

Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Bicara Therapeutics NASDAQ: BCAX said it made progress during the first quarter of 2026 on the devel

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the an

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-wee

This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider s

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage b

Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report)'s stock price hit a new 52-week high durin

BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage

Shares of Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report) reached a new 52-week high on We

The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bi

Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-H

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and

Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-W

Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW c

Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outp

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a B

Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript

CEO Claire Mazumdar sold 8,234 common shares for ~$154,000 between March 4 and March 6, 2026, at a w

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analy

Bicara Therapeutics Inc (BCAX) to release Q4 earnings on March 30. Expected loss of 65 cents/share.

B of A Securities analyst Tazeen Ahmad initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) wi

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bri

Citizens analyst Reni J. Benjamin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a

Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bri

BTIG analyst Jeet Mukherjee initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy r

Mizuho analyst Joseph Catanzaro initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Ne

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response

Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to brin

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-W

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.67) per share which missed the an

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the

https://www.sec.gov/Archives/edgar/data/2023658/000119312525230307/d54249ds3.htm

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a B